January 23, 2027

Prodromal Synucleinopathies: a time for action!

A one-day meeting at the Amphitheater of Eginitio Hospital, Athens

Theme 1. Assays for detecting aberrant alpha-synuclein in synucleinopathies, with a focus on prodromal states

Chair: Brit Mollenhauer, Marios Politis

Piero Parchi. The alpha-synuclein Seed Amplification Assay. 9.00-9.40

George Tofaris (or member of lab). Assays for detection of alpha-synuclein in extracellular vesicles and beyond. 9.40-10.20

Evangelia Emmanouilidou. ELISA-based assay for detection of aggregated alpha-synuclein. 10.20-10.45

Marios Politis. Developments in alpha-synuclein PET imaging. 10.45-11.10

Round Table Discussion on alpha-synuclein-based assays. 11.10-11.30

11.30-11.50. Coffee Break

Theme 2. Cohorts of prodromal synucleinopathies, with a focus on strategies for recruitment

Chair: Tasos Bonakis, Maria Stamelou

Enrollment and longitudinal follow-up of the biologically defined PPMI prodromal cohort . Ken Marek (or other PPMI representative). 11.50-12.30

HeBa international and how cohorts help identifying biomarkers for prodromal subjects towards disease. Brit Mollenhauer. 12.30-13.10

RBD: Alex Iranzo 13.10-13.50

The HELIAD Prodromal PD cohort: Nikos Scarmeas 13.50-14.15

Round Table Discussion on Cohorts. 14.15-14.30

Lunch. 14.30-15.15

Leonidas Sefanis. The special case of prodromal genetic PD. 15.15-15.40

Theme 3: Design of clinical trials in prodromal PD

Chair: Nikos Scarmeas. Leonidas Stefanis

Path to Prevention Platform Trial (P2P) in Stage 2B Neuronal Synuclein Disease (NSD) population. Ken Marek (or other PPMI representative). 15.40-16.20

NOR-RBD and INTERCEPT – the Norwegian Prevention Initiatives. Charalampos Tzoulis. 16.20-17.00

Round Table Discussion on clinical trials. 17.00-17.30